Instil Bio, Inc. filings document formal disclosures for a biotechnology issuer whose recent business focus has included novel therapeutic opportunities and subsidiary-level clinical programs through Axion Bio. Current reports on Form 8-K furnish quarterly and annual financial results, corporate updates, capital resources, restructuring and impairment charges, and material events tied to clinical-development and license-collaboration matters.
Proxy materials describe annual stockholder meeting matters, director elections, board governance, and ratification of the independent registered public accounting firm. Other 8-K disclosures record the change in certifying accountant, including the appointment of RSM US LLP and the replacement of Deloitte & Touche LLP.
Instil Bio, Inc. reported a much smaller net loss of $4.2 million for the quarter ended March 31, 2026, compared with $28.2 million a year earlier, as total operating expenses fell to $7.0 million from $30.6 million following major restructuring and the discontinuation of AXN-2510.
The company held $74.7 million in cash, cash equivalents, restricted cash and marketable securities and generated $2.2 million in rental income from its Tarzana facility, carried at $112.1 million as assets held for sale. Instil has an $85.6 million term loan maturing in January 2027, exceeding its liquid assets, which management identified as an indicator of substantial doubt about its ability to continue as a going concern. Management plans to exercise a contractual option to extend the loan to January 2028 and may refinance, sell the Tarzana facility, or raise additional equity or debt, and concluded these plans alleviate that substantial doubt.
Instil Bio reported first quarter 2026 results showing a much smaller loss and a solid cash position while it evaluates potential acquisitions and in-licensing opportunities for new therapeutics. As of March 31, 2026, the company held about $74.7 million in cash, cash equivalents, restricted cash and marketable securities and expects this to fund its current operating plan beyond 2027.
Net loss for the quarter was $4.2 million, or $0.62 per share, compared with $28.2 million, or $4.32 per share, a year earlier. On a non-GAAP basis, excluding stock-based compensation and restructuring and impairment charges, net loss was $2.2 million, or $0.32 per share, versus $8.6 million, or $1.32 per share.
Operating expenses declined sharply, with research and development at $0.7 million, general and administrative at $5.3 million, and restructuring and impairment charges at $1.0 million, all down significantly from the prior year period. Management highlighted an ongoing strategic shift toward building a focused pipeline through externally sourced assets, while cautioning there is no assurance any transaction will occur.
Instil Bio, Inc. is holding its 2026 Annual Meeting on June 11, 2026 at its Dallas headquarters. Stockholders will vote on electing two Class II directors, George Matcham and Neil Gibson, to serve until the 2029 meeting and on ratifying RSM US LLP as the new independent registered public accounting firm for 2026, following the Audit Committee’s April 1, 2026 decision to replace Deloitte & Touche LLP. Only holders of 6,781,976 common shares outstanding as of April 13, 2026 may vote, with one vote per share. The proxy also details board independence, committee structure, executive and director pay, ownership concentrations and change‑in‑control severance protections for senior management.
Instil Bio, Inc. is changing its independent auditor. The Audit Committee appointed RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, replacing Deloitte & Touche LLP, which was dismissed effective April 1, 2026.
Deloitte’s reports on the 2024 and 2025 consolidated financial statements contained no adverse opinions, disclaimers, or qualifications. The company reports no disagreements with Deloitte on accounting, disclosure, or audit scope, and no reportable events. Instil Bio also states it has not previously consulted RSM on accounting matters described in Regulation S‑K Item 304(a)(2).
Instil Bio is a small biotechnology company that has exited all prior development programs and currently has no product candidates in active development. In January 2026 it discontinued its former lead antibody AXN-2510 and terminated its related license, after earlier shutting down its tumor-infiltrating lymphocyte programs.
The company reported net losses of $71.4 million in 2025 and $74.1 million in 2024, with an accumulated deficit of $726.5 million as of December 31, 2025, and disclosed an indicator of substantial doubt about its ability to continue as a going concern. It held $76.3 million in cash, cash equivalents, restricted cash and marketable securities at year-end and is pursuing a strategy of in-licensing or acquiring new therapeutic assets. Instil also owns a 128,097‑square‑foot manufacturing facility in Tarzana, California, subject to a term loan maturing in 2027, and notes refinancing or sale risks around that debt. The company had 17 full‑time employees as of December 31, 2025.
Instil Bio reported its fourth quarter and full year 2025 results while outlining a strategic shift toward acquiring or in‑licensing new therapeutic candidates. In January 2026, its subsidiary Axion Bio discontinued clinical development of AXN-2510 and terminated a related license and collaboration agreement.
Cash, cash equivalents, restricted cash and marketable securities totaled $76.3 million as of December 31, 2025, down from $115.1 million a year earlier, and are expected to fund the current operating plan beyond 2027. For 2025, research and development expenses were $24.7 million, general and administrative expenses were $27.2 million, and restructuring and impairment charges were $16.6 million.
Instil reported a 2025 net loss of $71.4 million, or $10.70 per share, compared with a net loss of $74.1 million, or $11.39 per share, in 2024. On a non‑GAAP basis, excluding stock‑based compensation and restructuring and impairment charges, 2025 net loss was $46.1 million or $6.91 per share, an improvement from $49.4 million or $7.59 per share in 2024.
Instil Bio, Inc. (TIL) received an amended Schedule 13G filing showing that BML Investment Partners, L.P., a Delaware entity, beneficially owns 645,600 shares of Instil Bio common stock. This represents 9.5% of the outstanding common shares as of the event date.
BML reports shared voting and dispositive power over all 645,600 shares and no sole voting or dispositive power. The filing is certified as being made for investment purposes, not to change or influence control of Instil Bio.
Instil Bio, Inc. filed its Q3 2025 report, showing continued R&D investment and a narrower quarterly loss. The company reported a net loss of $13.6 million for the three months ended September 30, 2025. Cash, cash equivalents, restricted cash, marketable securities and long‑term investments totaled $83.4 million as of September 30, 2025.
Operating expenses were $15.0 million in the quarter, led by research and development of AXN‑2510/IMM2510 at $9.1 million, while general and administrative expenses were $5.9 million. Other rental income from the Tarzana facility contributed $2.2 million in the quarter. The Tarzana land and building were classified as assets held for sale at $112.1 million as of September 30, 2025.
Debt consisted of an outstanding principal of $85.6 million under a term loan bearing 6.35% interest, with interest‑only payments. During the nine months ended September 30, 2025, Instil raised $6.6 million net via its at‑the‑market program, issuing 185,837 shares. Shares outstanding were 6,781,976 as of November 11, 2025.
Instil Bio, Inc. (TIL) furnished a corporate update and financial results for the quarter ended September 30, 2025, via an accompanying press release.
The update was provided under Item 2.02 and the information is being furnished, not filed. Detailed results are included in Exhibit 99.1 to the report.